Histopathology最新文献

筛选
英文 中文
TERT dysregulation through intrachromosomal rearrangement in a skull-based soft tissue myoepithelial carcinoma. 颅骨软组织肌上皮癌中通过染色体内重排的TERT失调。
IF 3.9 2区 医学
Histopathology Pub Date : 2025-05-27 DOI: 10.1111/his.15464
Prokopios P Argyris, Kyle K VanKoevering, Daniel M Jones, Steve Oghumu, O Hans Iwenofu
{"title":"TERT dysregulation through intrachromosomal rearrangement in a skull-based soft tissue myoepithelial carcinoma.","authors":"Prokopios P Argyris, Kyle K VanKoevering, Daniel M Jones, Steve Oghumu, O Hans Iwenofu","doi":"10.1111/his.15464","DOIUrl":"https://doi.org/10.1111/his.15464","url":null,"abstract":"","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on 'The evolving molecular characterization, histological criteria and nomenclature of adenoid ameloblastoma as a World Health Organization tumour type'. 评论“腺样成釉细胞瘤作为世界卫生组织肿瘤类型的分子特征、组织学标准和命名”。
IF 3.9 2区 医学
Histopathology Pub Date : 2025-05-27 DOI: 10.1111/his.15475
Sampurna Raha, Rajiv S Desai, Shivani P Bansal, Pankaj M Shirsat, Pooja S Prasad
{"title":"Comment on 'The evolving molecular characterization, histological criteria and nomenclature of adenoid ameloblastoma as a World Health Organization tumour type'.","authors":"Sampurna Raha, Rajiv S Desai, Shivani P Bansal, Pankaj M Shirsat, Pooja S Prasad","doi":"10.1111/his.15475","DOIUrl":"https://doi.org/10.1111/his.15475","url":null,"abstract":"","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypical spindle cell/pleomorphic lipomatous tumour: a clinicopathologic, immunohistochemical and molecular study of 55 cases, highlighting TP53 gene alterations as a genetic hallmark of atypical pleomorphic lipomatous tumour. 非典型梭形细胞/多形性脂肪瘤:55例临床病理、免疫组织化学和分子研究,强调TP53基因改变是非典型多形性脂肪瘤的遗传标志。
IF 3.9 2区 医学
Histopathology Pub Date : 2025-05-23 DOI: 10.1111/his.15474
Fleur Cordier, Tony G Kleijn, Thomas Mentzel, Uta Flucke, Joost van Gorp, Liesbeth Ferdinande, Sarah Van Belle, Siebe Loontiens, Joni Van der Meulen, Jo Van Dorpe, Arjen H G Cleven, David Creytens
{"title":"Atypical spindle cell/pleomorphic lipomatous tumour: a clinicopathologic, immunohistochemical and molecular study of 55 cases, highlighting TP53 gene alterations as a genetic hallmark of atypical pleomorphic lipomatous tumour.","authors":"Fleur Cordier, Tony G Kleijn, Thomas Mentzel, Uta Flucke, Joost van Gorp, Liesbeth Ferdinande, Sarah Van Belle, Siebe Loontiens, Joni Van der Meulen, Jo Van Dorpe, Arjen H G Cleven, David Creytens","doi":"10.1111/his.15474","DOIUrl":"https://doi.org/10.1111/his.15474","url":null,"abstract":"<p><strong>Aims: </strong>Atypical spindle cell lipomatous tumour (ASLT) and atypical pleomorphic lipomatous tumour (APLT) have been grouped together under the umbrella designation atypical spindle cell/pleomorphic lipomatous tumour (ASPLT) in the 2020 edition of the World Health Organization (WHO) Classification of Soft Tissue and Bone Tumours. They are thought to exist on a morphologic spectrum and share similar clinicopathologic and biological characteristics. The aim of this study was to further explore the genetic background of ASLTs and APLTs by employing DNA-based next-generation sequencing and immunohistochemistry, with a specific focus on the TP53 gene.</p><p><strong>Methods and results: </strong>Using DNA-based NGS and immunohistochemistry, TP53 alterations were identified in 20 out of 21 APLT cases (95%). This is in contrast to the ASLT cases, in which no TP53 alterations could be observed. Among APLT cases with an abnormal p53 immunohistochemical profile and successful DNA NGS testing, 92% (12 of 13 cases) harboured a TP53 alteration.</p><p><strong>Conclusions: </strong>APLTs predominantly harbour a TP53 alteration in contrast to ASLT cases. Our findings support the classification of APLT as a distinct (sub)entity within a spectrum that overlaps with ASLT, and it remains to be determined whether the broader term 'ASPLT' will hold up. Furthermore, p53 immunostaining proved to be a potentially valuable diagnostic tool, aiding pathologists in differentiating between ASLT and APLT.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malignant ossifying fibromyxoid tumour with TP53::PHF1 fusion: report of three cases suggesting an association between rare fusions and malignant phenotypes. 恶性骨化纤维黏液样肿瘤伴TP53::PHF1融合:三例报告提示罕见融合与恶性表型之间的关联。
IF 3.9 2区 医学
Histopathology Pub Date : 2025-05-22 DOI: 10.1111/his.15471
Nathaniel J Bigot, Azfar Neyaz, Ali Alani, Arivarasan Karunamurthy, Robert D Bubar, Melissa A Burgess, Gregory W Charville, Ivy John
{"title":"Malignant ossifying fibromyxoid tumour with TP53::PHF1 fusion: report of three cases suggesting an association between rare fusions and malignant phenotypes.","authors":"Nathaniel J Bigot, Azfar Neyaz, Ali Alani, Arivarasan Karunamurthy, Robert D Bubar, Melissa A Burgess, Gregory W Charville, Ivy John","doi":"10.1111/his.15471","DOIUrl":"https://doi.org/10.1111/his.15471","url":null,"abstract":"","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current practices in prostate pathology reporting: results from a survey of genitourinary and general pathologists. 前列腺病理报告的当前实践:来自泌尿生殖系统和普通病理学家的调查结果。
IF 3.9 2区 医学
Histopathology Pub Date : 2025-05-13 DOI: 10.1111/his.15469
Mahra Nourbakshs, Liping Du, Andres M Acosta, Reza Alaghehbandan, Ali Amin, Mahul B Amin, Manju Aron, Daniel Berney, Fadi Brimo, Emily Chan, Liang Cheng, Maurizio Colecchia, Jasreman Dhillon, Michelle R Downes, Andrew J Evans, Lara R Harik, Oudai Hassan, Aiman Haider, Peter A Humphrey, Shilpy Jha, Shivani Kandukuri, Chia-Sui Sunny Kao, Seema Kaushal, Francesca Khani, Oleksandr N Kryvenko, Charlotte Kweldam, Priti Lal, Anandi Lobo, Fiona Maclean, Cristina Magi-Galluzzi, Rohit Mehra, Hiroshi Miyamoto, Sambit K Mohanty, Rodolfo Montironi, Gabriella Nesi, George Jabboure Netto, Jane K Nguyen, Maya Nourieh, Adeboye O Osunkoya, Gladell P Paner, Ankur R Sangoi, Rajal B Shah, John R Srigley, Maria Tretiakova, Patricia Troncoso, Kiril Trpkov, Theodorus H Van Der Kwast, Miao Zhang, Debra L Zynger, Sean R Williamson, Giovanna A Giannico
{"title":"Current practices in prostate pathology reporting: results from a survey of genitourinary and general pathologists.","authors":"Mahra Nourbakshs, Liping Du, Andres M Acosta, Reza Alaghehbandan, Ali Amin, Mahul B Amin, Manju Aron, Daniel Berney, Fadi Brimo, Emily Chan, Liang Cheng, Maurizio Colecchia, Jasreman Dhillon, Michelle R Downes, Andrew J Evans, Lara R Harik, Oudai Hassan, Aiman Haider, Peter A Humphrey, Shilpy Jha, Shivani Kandukuri, Chia-Sui Sunny Kao, Seema Kaushal, Francesca Khani, Oleksandr N Kryvenko, Charlotte Kweldam, Priti Lal, Anandi Lobo, Fiona Maclean, Cristina Magi-Galluzzi, Rohit Mehra, Hiroshi Miyamoto, Sambit K Mohanty, Rodolfo Montironi, Gabriella Nesi, George Jabboure Netto, Jane K Nguyen, Maya Nourieh, Adeboye O Osunkoya, Gladell P Paner, Ankur R Sangoi, Rajal B Shah, John R Srigley, Maria Tretiakova, Patricia Troncoso, Kiril Trpkov, Theodorus H Van Der Kwast, Miao Zhang, Debra L Zynger, Sean R Williamson, Giovanna A Giannico","doi":"10.1111/his.15469","DOIUrl":"https://doi.org/10.1111/his.15469","url":null,"abstract":"<p><strong>Aims: </strong>Standardizing pathology reporting protocols through peer consensus review is critical for the best quality of care metrics. Reporting heterogeneity due to discrepancies among professional societies and practice patterns may lead to heterogeneous management and treatment approaches. This issue prompted a multi-institutional survey of pathologists to address potential similarities or differences in trends and practice patterns in prostate pathology reporting worldwide.</p><p><strong>Methods and results: </strong>A REDCap survey was distributed among 175 pathologists worldwide, recruited through invitations and social media. The response rate among invited pathologists was 83%. The practice locations were as follows: North America (USA, Canada, and Mexico, 62%), Europe (17%), Australia/New Zealand (3%), Central/South America (2%), Asia (13%), and Africa (2%). Most pathologists practiced for <5 years (28%). A genitourinary (GU) pathology fellowship was completed by 37%, 58% practiced in a subspecialized setting, and 43% in academia. Reporting includes (63%) or subtracts (37%) intervening benign tissue. Both Gleason score and Grade Groups (GG)s were reported by 96% of responders, whereas 94% report percent pattern 4 (%4). Aggregate grading and volume estimation in undesignated cores with different grades in the same jar are reported by 73% and 54% for systematic biopsies, and 83% and 62% for targeted biopsies, respectively. Cribriform morphology was reported by 81%. For presumed intraductal carcinoma (IDC), 89% use basal cell markers when isolated (iIDC), 82% with GG1 cancer, and 37% with ≥GG2. iIDC or IDC associated with GG1 or with ≥GG2 was not graded by 90%, 78%, and 70%, respectively. In radical prostatectomies, 90% report %4, but only 53% report it if the overall grade is ≥7. A tumour with Gleason 3 + 3 = 6 and <5% pattern 4 was graded as GG2 by 64%. A <5% cutoff for defining tertiary pattern was used by 74%, and 80% report >5% pattern 4 or 5 as a secondary pattern. Grading was assigned based on the dominant nodule by 59%. Finally, reporting practices were significantly associated with demographic characteristics.</p><p><strong>Conclusions: </strong>Although most issues are agreed upon, significant discordance is identified among societies and pathologists in different practice settings. We hope this survey will serve as the basis for future studies and new collaborative approaches to more standardized reporting practices.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection. ROS1免疫组化作为乳腺癌ROS1靶向治疗的潜在预测生物标志物:抗体克隆选择的影响
IF 3.9 2区 医学
Histopathology Pub Date : 2025-05-13 DOI: 10.1111/his.15465
Anna Sokolova, Vaibhavi Joshi, Haarika Chittoory, Michael Walsh, Malcolm Lim, Jamie R Kutasovic, Kaltin Ferguson, Peter T Simpson, Sunil R Lakhani, Amy E McCart Reed
{"title":"ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection.","authors":"Anna Sokolova, Vaibhavi Joshi, Haarika Chittoory, Michael Walsh, Malcolm Lim, Jamie R Kutasovic, Kaltin Ferguson, Peter T Simpson, Sunil R Lakhani, Amy E McCart Reed","doi":"10.1111/his.15465","DOIUrl":"https://doi.org/10.1111/his.15465","url":null,"abstract":"<p><strong>Aims: </strong>Invasive lobular carcinoma (ILC) may show targetable vulnerabilities secondary to the characteristic loss of the cell adhesion protein E-cadherin. Specifically, a synthetic lethal interaction was identified between E-cadherin loss and ROS1 inhibition. Several clinical trials are currently under way to assess the efficacy of ROS1 inhibitors in ILC; however, ROS1 expression has not been confirmed in ILC tumours and ROS1 has not been validated as a biomarker in the breast cancer setting. This study aimed to (i) examine ROS1 expression in a large cohort of breast cancer cases and (ii) investigate the biology and clinical significance of ROS1 positivity in breast cancer.</p><p><strong>Methods and results: </strong>ROS1 immunohistochemistry was performed on a large cohort of ILC (n = 274) and invasive carcinoma of no special type (NST; n = 431) cases with extensive clinicopathological data. The staining performance of four ROS1 antibody clones was compared. There was marked variation in ROS1 status according to antibody clone. D4D6 and SP384 were negative in almost all breast cancer cases, whereas EP282 and EPMGHR2 were positive in 37 and 47% of ILC cases, and 49 and 74% of NST cases, respectively. Only data from clones D4D6 and SP384 were highly concordant, while EP282 and EPMGHR2 were positive in distinct breast cancer subtypes.</p><p><strong>Conclusions: </strong>Assessment of ROS1 status in breast cancer appears to be highly antibody clone-dependent. ROS1 antibody clone selection will be an important consideration in the design of clinical trials investigating the clinical validity of ROS1 as a predictive biomarker in breast cancer.</p>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to 'Peculiar nuclear atypia associated with MDM2 gene amplification in carcinoma ex-pleomorphic adenoma harbouring an alteration of HMGA2'. 修正“HMGA2改变的癌前多形性腺瘤中与MDM2基因扩增相关的特殊核异型性”。
IF 3.9 2区 医学
Histopathology Pub Date : 2025-05-07 DOI: 10.1111/his.15466
{"title":"Correction to 'Peculiar nuclear atypia associated with MDM2 gene amplification in carcinoma ex-pleomorphic adenoma harbouring an alteration of HMGA2'.","authors":"","doi":"10.1111/his.15466","DOIUrl":"https://doi.org/10.1111/his.15466","url":null,"abstract":"","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "Understanding and overcoming the pitfalls in the diagnosis of pleomorphic and carcinoma ex-pleomorphic adenoma of salivary glands". 更正“认识和克服涎腺多形性腺瘤和癌前多形性腺瘤的诊断误区”。
IF 3.9 2区 医学
Histopathology Pub Date : 2025-05-07 DOI: 10.1111/his.15467
{"title":"Correction to \"Understanding and overcoming the pitfalls in the diagnosis of pleomorphic and carcinoma ex-pleomorphic adenoma of salivary glands\".","authors":"","doi":"10.1111/his.15467","DOIUrl":"https://doi.org/10.1111/his.15467","url":null,"abstract":"","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SOX17 expression in normal mesothelium and mesothelial lesions. SOX17在正常间皮及间皮病变中的表达。
IF 3.9 2区 医学
Histopathology Pub Date : 2025-05-06 DOI: 10.1111/his.15470
Zaibo Li, Qingqing Ding, Deyin Xing, Anil V Parwani
{"title":"SOX17 expression in normal mesothelium and mesothelial lesions.","authors":"Zaibo Li, Qingqing Ding, Deyin Xing, Anil V Parwani","doi":"10.1111/his.15470","DOIUrl":"https://doi.org/10.1111/his.15470","url":null,"abstract":"","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The utility of deeper levels in evaluating transbronchial cryobiopsy specimens for interstitial lung disease. 在评估间质性肺疾病经支气管低温活检标本中的应用。
IF 3.9 2区 医学
Histopathology Pub Date : 2025-05-06 DOI: 10.1111/his.15468
Peter Manchen, Michelle Garlin Politis, Andrew Churg, Katrina Pfefferle, Melissa Monroy-Lopez, Yasmeen Butt, Brandon T Larsen, Maxwell L Smith, Joanne L Wright, Henry D Tazelaar
{"title":"The utility of deeper levels in evaluating transbronchial cryobiopsy specimens for interstitial lung disease.","authors":"Peter Manchen, Michelle Garlin Politis, Andrew Churg, Katrina Pfefferle, Melissa Monroy-Lopez, Yasmeen Butt, Brandon T Larsen, Maxwell L Smith, Joanne L Wright, Henry D Tazelaar","doi":"10.1111/his.15468","DOIUrl":"https://doi.org/10.1111/his.15468","url":null,"abstract":"","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信